OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

-   Q3 revenue of $26.1 million, increased 22% year-over-year
-   Q3 gross profit increased 30% year-over-year to $17.5 million
-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million
-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million
-   Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3